SANOFI-AVENTIS PURCHASES TARGEGEN, DEVELOPER OF DRUGS FOR MYELOPROLIFERATIVE DISORDERS

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment.

For the full press release click here.